James Sellman
Psychiatry · Richmond, VANPI 1225118805
Payments from drug & device makers
Across 910 payments — averaging $20.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Otsuka America Pharmaceutical, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Johnson & Johnson$1K
- Vanda Pharmaceuticals Inc.$1K
- Alkermes, Inc.$946
- plus $8K from 31 others
What the payments were for
- Food & beverage$18,24199%
- Education$941%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$870
- VRAYLAR$724
- CAPLYTA$721
- REXULTI$488
- INGREZZA$484
- Fanapt$477
- Austedo XR$374
- INVEGA SUSTENNA$230
- NUEDEXTA$125
- Quillichew ER$125
- Quillivant$125
- Dyanavel XR$125
- ABILIFY MAINTENA$125
- INVEGA$125
- AUSTEDO$123
- COBENFY$119
- Auvelity$119
- Jornay PM 20mg capsules (Bottle of 100)$114
How this compares
$18,334 in reported general payments places this provider in the 95th percentile of 884 psychiatry providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuedextaDextromethorphan Hbr/Quinidine | 23 | $40,888 |
| RexultiBrexpiprazole | 16 | $34,405 |
| VraylarCariprazine Hcl | 18 | $26,629 |
| TrintellixVortioxetine Hydrobromide | 24 | $21,947 |
| VyvanseLisdexamfetamine Dimesylate | 21 | $9,305 |
| Lamotrigine ErLamotrigine | 25 | $9,282 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 116 | $5,373 |
| ConcertaMethylphenidate Hcl | 11 | $4,194 |
| Lurasidone Hcl | 11 | $3,398 |
| Vilazodone Hcl | 19 | $2,298 |
| Lamotrigine | 106 | $1,933 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 33 | $1,878 |
| Trazodone Hcl | 106 | $1,327 |
| Bupropion XlBupropion Hcl | 33 | $801 |
| Gabapentin | 66 | $764 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Avanir Pharmaceuticals, Inc.Nuedexta | $756 | $40,88823 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $2,296 | $34,40516 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $330 | $31,25145 claims |
| AbbVieVraylar | $2,901 | $26,62918 claims |
| Johnson & JohnsonConcerta | $1,286 | $4,19411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 884 psychiatry providers in Virginia.
Other psychiatry in Richmond
- Frederick MoellerRichmond$678K
- Susan KornsteinRichmond$87K
- Ashvin PatelRichmond$68K
- Joel SteinbergRichmond$40K
- Robert SewardRichmond$14K
- William KernodleRichmond$14K
- John LeeRichmond$10K
- Niku SinghFalls Church$2.5M
- David ScheidererRoanoke$2.4M
- Kent McDanielGlen Allen$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.